Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma (SOPT)
KCT0006739Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Mar 2022
- Countries
- 1
- Sponsor
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Drugs
- sorafenib
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Hanmi Pharmaceutical. Started Mar 2022; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Sorafenib monotherapy
Single-group Phase 2 treatment arm where all enrolled patients with previously treated advanced hepatocellular carcinoma receive sorafenib.
03
Who it enrols
Adults with advanced hepatocellular carcinoma who have previously received systemic anticancer therapy.
Beyond the preview
Go deeper on KCT0006739.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006739.